Changes

'''Gardasil''', the recently-available HPV vaccine, protects against types 6, 11, 16 and 18 of the human papillomavirus (HPV), which are sexually transmitted diseases that are endemic among promiscuous people, with 80% of those who have sex outside of marriage suffering from the disease.<ref>http://www.hopkinsmedicine.org/hnf/hnf_6403.htm</ref>  These strains of HPV have been associated with 70% of cervical cancer cases and may also play a role in the development of other types of cancer <ref>[http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref>. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on the results of four separate studies which showed elevated [[antibody]] levels in 20,000 recipients of the vaccine.<ref> http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm</ref>  Although the study period was not long enough to see if cervical cancer to develop, the studies did show that the vaccine was 100% effective in preventing the pre-cancerous lesions and genital warts caused by HPV <ref>http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html</ref>without reviewing any epidemiological studies and merely monitoring for a brief period elevated [[antibody]] levels in recipients of the vaccine.

'''Gardasil''', the recently-available HPV vaccine, protects against types 6, 11, 16 and 18 of the human papillomavirus (HPV), which are sexually transmitted diseases that are endemic among promiscuous people, with 80% of those who have sex outside of marriage suffering from the disease.<ref>http://www.hopkinsmedicine.org/hnf/hnf_6403.htm</ref>  These strains of HPV have been associated with 70% of cervical cancer cases and may also play a role in the development of other types of cancer <ref>[http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref>. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on the results of four separate studies which showed elevated [[antibody]] levels in 20,000 recipients of the vaccine.<ref> http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm</ref>  Although the study period was not long enough to see if cervical cancer to develop, the studies did show that the vaccine was 100% effective in preventing the pre-cancerous lesions and genital warts caused by HPV <ref>http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html</ref>

The long-term consequences of the HPV vaccine are not known and there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.

The long-term consequences of the HPV vaccine are not known and there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.